NZ701190A - Combination meloxicam and xylazine therapy in animals - Google Patents

Combination meloxicam and xylazine therapy in animals

Info

Publication number
NZ701190A
NZ701190A NZ701190A NZ70119013A NZ701190A NZ 701190 A NZ701190 A NZ 701190A NZ 701190 A NZ701190 A NZ 701190A NZ 70119013 A NZ70119013 A NZ 70119013A NZ 701190 A NZ701190 A NZ 701190A
Authority
NZ
New Zealand
Prior art keywords
meloxicam
xylazine
combination
animals
therapy
Prior art date
Application number
NZ701190A
Inventor
Guiseppe Pippia
Original Assignee
Troy Lab Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012901666A external-priority patent/AU2012901666A0/en
Application filed by Troy Lab Pty Ltd filed Critical Troy Lab Pty Ltd
Publication of NZ701190A publication Critical patent/NZ701190A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention comprises both meloxicam and xylazine containing compositions and methods of their administration in the field of veterinary pharmaceuticals. A meloxicam and xylazine formulation is provided which is adapted for oral administration. A method is also provided to form a combination meloxicam and xylazine formulation from meloxicam and xyalzine formulations including directions as to concentrations and dosages for sheep and cattle, the target species for the formulations.
NZ701190A 2012-04-27 2013-04-26 Combination meloxicam and xylazine therapy in animals NZ701190A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2012901666A AU2012901666A0 (en) 2012-04-27 Combination of meloxicam and xylazine therapy in animals
PCT/AU2013/000429 WO2013159151A1 (en) 2012-04-27 2013-04-26 Combination meloxicam and xylazine therapy in animals

Publications (1)

Publication Number Publication Date
NZ701190A true NZ701190A (en) 2016-07-29

Family

ID=49482035

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ701190A NZ701190A (en) 2012-04-27 2013-04-26 Combination meloxicam and xylazine therapy in animals

Country Status (4)

Country Link
EP (1) EP2841072A4 (en)
AU (3) AU2013252491A1 (en)
NZ (1) NZ701190A (en)
WO (1) WO2013159151A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8702523A (en) * 1986-11-03 1988-06-01 Sandoz Ag PHARMACEUTICAL PREPARATIONS WITH ANALGETIC ACTION AND METHOD FOR PREPARING OR PREPARING AND USING THESE PREPARATIONS.
ES2490595T3 (en) * 2005-02-17 2014-09-04 Abbott Laboratories Transmucosal administration of drug compositions to treat and prevent disorders in animals
WO2007072503A2 (en) * 2005-12-21 2007-06-28 Panacea Biotec Ltd. Combinations for managing inflammation and associated disorders
UY30636A1 (en) * 2006-10-18 2008-05-02 Senosiain Lab PHARMACEUTICAL COMPOSISION OF MODIFIED LIBERATION OF A RELAXING MUSCLE AND AN NSAID
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8791105B2 (en) * 2010-07-14 2014-07-29 Kansas State University Research Foundation Methods for alleviating chronic pain and improving performance of cattle undergoing dehorning or castration

Also Published As

Publication number Publication date
AU2018201002A1 (en) 2018-03-01
AU2017101084A4 (en) 2017-09-07
WO2013159151A1 (en) 2013-10-31
AU2017101084B4 (en) 2017-11-02
AU2013252491A1 (en) 2014-11-06
EP2841072A1 (en) 2015-03-04
EP2841072A4 (en) 2016-01-06

Similar Documents

Publication Publication Date Title
MX2018015892A (en) Boronic acid derivatives and therapeutic uses thereof.
MX2021015234A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan.
EA201691988A1 (en) DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
BR112014024833A8 (en) VETERINARY SOFT CHEWABLE PHARMACEUTICAL PRODUCT, PROCESS FOR MANUFACTURING A PRODUCT, USE OF PAMOIC ACID OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, USE OF A SOFT CHEWABLE VETERINARY PHARMACEUTICAL COMPOSITION, AND, SOFT CHEWABLE VETERINARY PHARMACEUTICAL COMPOSITION.
EA201692301A1 (en) DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
MD4577C1 (en) Chewable veterinary compositions comprising an isoxazoline active agent and their use in the treatment and/or prophylaxis of a parasitic infection and infestation
MX2016004035A (en) Long-acting spiro-isoxazoline formulations.
EA201591003A1 (en) DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
MX2013011086A (en) (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases.
PE20150199A1 (en) PHARMACEUTICAL COMPOSITIONS AND TREATMENT OF MASTITIS
EA201690386A1 (en) COMPOUNDS AND COMPOSITIONS AS MEK INHIBITORS
MX2022015141A (en) Compositions and methods of use of an inappetance-controlling compound.
NZ706990A (en) A veterinary method of alleviating noise aversion
BR112013010136A2 (en) vaccine, therapeutic composition and methods for the treatment or inhibition of gliblastoma
BR112015022846A2 (en) use of a compound to treat or prevent a bradykinin b2 receptor mediated angioedema and formulation comprising the same
MX2019006773A (en) Dexmedetomidine or medetomidine for use in treating separation anxiety in dogs.
PH12014502065A1 (en) Vesicular formulations
EA201390345A1 (en) THERAPEUTIC HOSE MEDICINE
UA117751C2 (en) Tylosin derivatives and method for preparation thereof
BR112015032262A2 (en) nanoparticle compositions and piperazine compound formulations
TR201908936T4 (en) Use of palmitoylethanolamide in combination with opioids.
EA201590097A1 (en) COMPOSITIONS WITH SINGLE DOSE FOR ORAL ADMINISTRATION AND METHODS OF TREATING CATS WITH THE HELP OF SPINOSADE DESTROYING ECT PARASITES
NZ701190A (en) Combination meloxicam and xylazine therapy in animals
NZ717434A (en) A veterinary method for inducing emesis
EA201500014A1 (en) MEANS FOR TREATING COCKIDIOSIS IN BIRDS AND ANIMALS

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2018 BY PETER MAXWELL + ASSOCIATES

Effective date: 20170407

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2019 BY PETER MAXWELL + ASSOCIATES

Effective date: 20180201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2020 BY PETER MAXWELL + ASSOCIATES

Effective date: 20190212

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2021 BY PETER MAXWELL + ASSOCIATES

Effective date: 20200218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2022 BY MAXWELLS PATENT + TRADE MARK ATTORNEYS PTY LTD

Effective date: 20210531

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2023 BY MAXWELLS PATENT + TRADE MARK ATTORNEYS PTY LTD

Effective date: 20220419

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2024 BY GRIFFITH HACK

Effective date: 20231025